Verrica Pharmaceuticals Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Verrica Pharmaceuticals Inc. (VRCA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $117.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-03-11
- Verrica Pharmaceuticals Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $117.00K, a 39.06% decline from fiscal 2024.
- Verrica Pharmaceuticals Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $192.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2025-12-31 | $117.00K 10-K · filed 2026-03-11 |
| 2024-12-31 | $192.00K 10-K · filed 2026-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |